BREAKING NEWS: Pfizer and Moderna expand their COVID-19 vaccine clinical trials in children aged 5-11 at urging of FDA
- Pfizer-BioNTech and Moderna are being asked by the FDA to expand the number of children aged 5-11 in their COVID-19 vaccine clinical trials
- Currently, the companies have 3,000 children each, but could now see the number of participants double to 6,000
- The move is to help detect rare cases of heart inflammation seen in people under age 30 who have been vaccinated
Pfizer-BioNTech and Moderna are expanding the sizes of their COVID-19 vaccine clinical trials in children ages five to 11 at the urging of the U.S. Food and Drug Administration (FDA).
Multiple sources told The New York Times that the move is to help detect cases of rare heart inflammation that have occurred in vaccinated people under age 30.
When the studies began, Pfizer and Moderna has been asked to include at 3,000 children between ages five to 11.
However, the companies are now being asked to as much as double the number of pediatric participants.
Pfizer-BioNTech and Moderna are being asked by the FDA to expand the number of children aged 5-11 in their COVID-19 vaccine clinical trials. Pictured: Eloise LaCour, three, gets either a vaccine or placebo as part of Phase 1 clinical trials of use of the Pfizer-BioNTech vaccine
This is a breaking news story and will be updated.